Home / WXXWY : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does WXXWY make money? Does WXXWY have pricing power? What's the Earnings Whisper? Will WXXWY profit more as the business scales? What is WXXWY's management track record? Is WXXWY's current price justified?

WuXi Biologics (Cayman) Inc.

$12.01 +$3.66 (+43.83%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$11.96

Day Range

$11.88$12.22

Year Range

$7.3$13.43

Market Cap

24.66B

AVG Volume

78.31K

Trailing/Forward PE

33.22/3.27

PEG ratio

1.35

Dividend Yield

Next Earnings Date

2027-03-23

Primary Exchange

Other OTC

Revenue (CNY)

WXXWY Revenue (CNY) by quarter
Period	Revenue (CNY)
26 Q2	11.66B
25 Q4	11.62B
25 Q2	9.95B
24 Q4	10.1B
24 Q2	8.57B
23 Q4	8.54B
23 Q2	8.49B
22 Q4	8.06B
22 Q2	7.21B
21 Q4	5.88B

Net Income (CNY)

WXXWY Net Income (CNY) by quarter
Period	Net Income (CNY)
26 Q2	2.41B
25 Q4	2.52B
25 Q2	2.34B
24 Q4	1.86B
24 Q2	1.5B
23 Q4	1.13B
23 Q2	2.27B
22 Q4	1.89B
22 Q2	2.54B
21 Q4	1.55B

Operating Income (CNY)

WXXWY Operating Income (CNY) by quarter
Period	Operating Income (CNY)
26 Q2	3.69B
25 Q4	3.85B
25 Q2	2.72B
24 Q4	3.15B
24 Q2	1.82B
23 Q4	1.65B
23 Q2	2.3B
22 Q4	1.87B
22 Q2	2.48B
21 Q4	1.53B

EBITDA (CNY)

WXXWY EBITDA (CNY) by quarter
Period	EBITDA (CNY)
26 Q2	4.34B
25 Q4	4.72B
25 Q2	3.36B
24 Q4	3.96B
24 Q2	2.47B
23 Q4	2.27B
23 Q2	2.66B
22 Q4	2.17B
22 Q2	2.9B
21 Q4	1.7B

Cash Flows (CNY)

WXXWY Cash Flows (CNY) by quarter
Period	Cash Flows (CNY)
26 Q2	0
25 Q4	2.79B
25 Q2	4.98M
24 Q4	1.85B
24 Q2	-565.26M
23 Q4	218.6M
23 Q2	218.6M
22 Q4	899.87M
22 Q2	-1.23B
21 Q4	198.58M

EPS (CNY)

WXXWY EPS (CNY) by quarter
Period	EPS (CNY)
26 Q2	1.16
25 Q4	1.18
25 Q2	1.1
24 Q4	0.86
24 Q2	0.7
23 Q4	0.52
23 Q2	1.04
22 Q4	0.86
22 Q2	1.16
21 Q4	0.7

Expenses (CNY)

WXXWY Expenses (CNY) by quarter
Period	Expenses (CNY)
26 Q2	1.7B
25 Q4	3.61B
25 Q2	1.79B
24 Q4	3.6B
24 Q2	3.4B
23 Q4	3.74B
23 Q2	3.37B
22 Q4	4.64B
22 Q2	3.61B
21 Q4	3.43B

Cash & Debt (CNY)

WXXWY Cash & Debt (CNY) by quarter
Period	Cash & Debt (CNY)
26 Q2	13.04B
25 Q4	15.75B
25 Q2	11.6B
24 Q4	10.71B
24 Q2	9.53B
23 Q4	11.24B
23 Q2	7.6B
22 Q4	6.7B
22 Q2	8.47B
21 Q4	10.15B

Debt ratios

WXXWY Debt ratios by quarter
Period	Debt ratios
26 Q2	-0.63
25 Q4	-0.87
25 Q2	-0.54
24 Q4	-0.51
24 Q2	-0.52
23 Q4	-0.67
23 Q2	-0.26
22 Q4	-0.26
22 Q2	-0.53
21 Q4	-1.09

Margins

WXXWY Margins by quarter
Period	Margins
26 Q2	46.22%
25 Q4	48.71%
25 Q2	42.73%
24 Q4	42.58%
24 Q2	39.07%
23 Q4	38.25%
23 Q2	41.93%
22 Q4	41.07%
22 Q2	47.36%
21 Q4	43.04%

Return on Capital

WXXWY Return on Capital by quarter
Period	Return on Capital
26 Q2	4.42%
25 Q4	4.75%
25 Q2	4.77%
24 Q4	4.08%
24 Q2	3.36%
23 Q4	2.57%
23 Q2	5.81%
22 Q4	5.21%
22 Q2	7.14%
21 Q4	4.73%

Shares Outstanding

WXXWY Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	2.05B
25 Q4	1.99B
25 Q2	2.09B
24 Q4	2.04B
24 Q2	2.15B
23 Q4	2.24B
23 Q2	2.18B
22 Q4	2.19B
22 Q2	2.19B
21 Q4	2.21B

Book Value Per Share (CNY)

WXXWY Book Value Per Share (CNY) by quarter
Period	Book Value Per Share (CNY)
26 Q2	26.63
25 Q4	26.67
25 Q2	23.44
24 Q4	22.28
24 Q2	20.74
23 Q4	19.63
23 Q2	17.91
22 Q4	16.51
22 Q2	16.24
21 Q4	14.81

Total Assets (CNY)

WXXWY Total Assets (CNY) by quarter
Period	Total Assets (CNY)
26 Q2	65.39B
25 Q4	63.74B
25 Q2	60.44B
24 Q4	56.98B
24 Q2	56.11B
23 Q4	56.58B
23 Q2	52.14B
22 Q4	49.56B
22 Q2	47.47B
21 Q4	44.03B

PE Ratio

WXXWY PE Ratio by quarter
Period	PE Ratio
Sep 26	19.51
Sep 26	20.4
Aug 26	21.06
Aug 26	21.01
Aug 26	19.39
Aug 26	19.05
Jul 26	16.12
Jul 26	16.28
Jul 26	15.59
Jul 26	15.85
Jul 26	14.89
Jun 26	14.16
Jun 26	12.67
Jun 26	12.92
Jun 26	13.4
May 26	14.22
May 26	13.64
May 26	14.02
May 26	13.6
May 26	14.13
Apr 26	14.29
Apr 26	15.5
Apr 26	15.16
Apr 26	14.94
Mar 26	17.16
Mar 26	17.56
Mar 26	18.49
Mar 26	19.32
Feb 26	21.46
Feb 26	22.06
Feb 26	22.34
Feb 26	20.74
Jan 26	20.05
Jan 26	21.4
Jan 26	21.74
Jan 26	20.42
Jan 26	17.9
Dec 25	18.08
Dec 25	18.77
Dec 25	18.08
Dec 25	18.2
Nov 25	17.56
Nov 25	17.05
Nov 25	18.45
Nov 25	18.95
Oct 25	20.63
Oct 25	20.34
Oct 25	20.36
Oct 25	19.79
Oct 25	23.67
Sep 25	21.59
Sep 25	20.89
Sep 25	20.08
Sep 25	20.15
Aug 25	18.31
Aug 25	18.51
Aug 25	17.33
Aug 25	16.28
Aug 25	17.06
Jul 25	17.26
Jul 25	15.83
Jul 25	14.64
Jul 25	13.97
Jun 25	13.8
Jun 25	13.06
Jun 25	14.97
Jun 25	13.29
May 25	13.7
May 25	13.25
May 25	13.07
May 25	12.79
May 25	13.51
Apr 25	12.77
Apr 25	11.4
Apr 25	11.37
Apr 25	12.67
Mar 25	15.34
Mar 25	15.54
Mar 25	15.77
Mar 25	14.09
Feb 25	13.28
Feb 25	15.32
Feb 25	13.44
Feb 25	12.55
Jan 25	10.99
Jan 25	10.85
Jan 25	10.78
Jan 25	9.98
Jan 25	10.03
Dec 24	10.19
Dec 24	10.11
Dec 24	10.45
Dec 24	10.12
Nov 24	8.64
Nov 24	8.43
Nov 24	8.72
Nov 24	9.63
Nov 24	9.35
Oct 24	10
Oct 24	9.53

Free Cash Flow Yield

WXXWY Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	2.54%
Sep 26	2.43%
Aug 26	2.36%
Aug 26	2.36%
Aug 26	2.56%
Aug 26	2.61%
Jul 26	3.08%
Jul 26	3.05%
Jul 26	3.18%
Jul 26	3.13%
Jul 26	3.33%
Jun 26	3.51%
Jun 26	3.92%
Jun 26	3.84%
Jun 26	3.7%
May 26	3.49%
May 26	3.64%
May 26	3.54%
May 26	3.65%
May 26	3.51%
Apr 26	3.47%
Apr 26	3.2%
Apr 26	3.27%
Apr 26	3.32%
Mar 26	1.29%
Mar 26	1.26%
Mar 26	1.2%
Mar 26	1.15%
Feb 26	1.03%
Feb 26	1%
Feb 26	0.99%
Feb 26	1.07%
Jan 26	1.1%
Jan 26	1.03%
Jan 26	1.02%
Jan 26	1.08%
Jan 26	1.24%
Dec 25	1.22%
Dec 25	1.18%
Dec 25	1.22%
Dec 25	1.22%
Nov 25	1.26%
Nov 25	1.3%
Nov 25	1.2%
Nov 25	1.17%
Oct 25	1.07%
Oct 25	1.09%
Oct 25	1.09%
Oct 25	1.12%
Oct 25	0.93%
Sep 25	1.18%
Sep 25	1.22%
Sep 25	1.27%
Sep 25	1.27%
Aug 25	1.39%
Aug 25	1.38%
Aug 25	1.47%
Aug 25	1.57%
Aug 25	1.5%
Jul 25	1.48%
Jul 25	1.61%
Jul 25	1.74%
Jul 25	1.83%
Jun 25	1.85%
Jun 25	1.95%
Jun 25	1.71%
Jun 25	1.92%
May 25	1.86%
May 25	1.93%
May 25	1.95%
May 25	2%
May 25	1.89%
Apr 25	2%
Apr 25	2.24%
Apr 25	2.25%
Apr 25	2.02%
Mar 25	0.74%
Mar 25	0.73%
Mar 25	0.72%
Mar 25	0.81%
Feb 25	0.86%
Feb 25	0.74%
Feb 25	0.85%
Feb 25	0.91%
Jan 25	1.03%
Jan 25	1.05%
Jan 25	1.06%
Jan 25	1.14%
Jan 25	1.13%
Dec 24	1.12%
Dec 24	1.12%
Dec 24	1.09%
Dec 24	1.12%
Nov 24	1.32%
Nov 24	1.35%
Nov 24	1.31%
Nov 24	1.18%
Nov 24	1.22%
Oct 24	1.14%
Oct 24	1.19%

Price to Sales

WXXWY Price to Sales by quarter
Period	Price to Sales
Sep 26	3.98
Sep 26	4.16
Aug 26	4.3
Aug 26	4.29
Aug 26	3.96
Aug 26	3.89
Jul 26	3.29
Jul 26	3.32
Jul 26	3.18
Jul 26	3.24
Jul 26	3.04
Jun 26	2.89
Jun 26	2.59
Jun 26	2.64
Jun 26	2.74
May 26	2.9
May 26	2.78
May 26	2.86
May 26	2.78
May 26	2.89
Apr 26	2.92
Apr 26	3.16
Apr 26	3.1
Apr 26	3.05
Mar 26	3.15
Mar 26	3.23
Mar 26	3.4
Mar 26	3.55
Feb 26	3.94
Feb 26	4.05
Feb 26	4.1
Feb 26	3.81
Jan 26	3.68
Jan 26	3.93
Jan 26	3.99
Jan 26	3.75
Jan 26	3.29
Dec 25	3.32
Dec 25	3.45
Dec 25	3.32
Dec 25	3.34
Nov 25	3.23
Nov 25	3.13
Nov 25	3.39
Nov 25	3.48
Oct 25	3.79
Oct 25	3.74
Oct 25	3.74
Oct 25	3.63
Oct 25	4.35
Sep 25	4.08
Sep 25	3.95
Sep 25	3.8
Sep 25	3.81
Aug 25	3.46
Aug 25	3.5
Aug 25	3.28
Aug 25	3.08
Aug 25	3.23
Jul 25	3.27
Jul 25	2.99
Jul 25	2.77
Jul 25	2.64
Jun 25	2.61
Jun 25	2.47
Jun 25	2.83
Jun 25	2.51
May 25	2.59
May 25	2.51
May 25	2.47
May 25	2.42
May 25	2.56
Apr 25	2.42
Apr 25	2.16
Apr 25	2.15
Apr 25	2.4
Mar 25	3.09
Mar 25	3.13
Mar 25	3.18
Mar 25	2.84
Feb 25	2.68
Feb 25	3.09
Feb 25	2.71
Feb 25	2.53
Jan 25	2.21
Jan 25	2.19
Jan 25	2.17
Jan 25	2.01
Jan 25	2.02
Dec 24	2.05
Dec 24	2.04
Dec 24	2.11
Dec 24	2.04
Nov 24	1.74
Nov 24	1.7
Nov 24	1.76
Nov 24	1.94
Nov 24	1.88
Oct 24	2.02
Oct 24	1.92

EV/EBITDA

WXXWY EV/EBITDA by quarter
Period	EV/EBITDA
Sep 26	10.18
Sep 26	10.68
Aug 26	11.06
Aug 26	11.03
Aug 26	10.11
Aug 26	9.92
Jul 26	8.26
Jul 26	8.35
Jul 26	7.96
Jul 26	8.11
Jul 26	7.57
Jun 26	7.15
Jun 26	6.31
Jun 26	6.45
Jun 26	6.72
May 26	7.19
May 26	6.86
May 26	7.07
May 26	6.83
May 26	7.14
Apr 26	7.22
Apr 26	7.91
Apr 26	7.72
Apr 26	7.59
Mar 26	9.18
Mar 26	9.41
Mar 26	9.94
Mar 26	10.41
Feb 26	11.62
Feb 26	11.96
Feb 26	12.12
Feb 26	11.21
Jan 26	10.82
Jan 26	11.59
Jan 26	11.78
Jan 26	11.03
Jan 26	9.6
Dec 25	9.71
Dec 25	10.1
Dec 25	9.7
Dec 25	9.77
Nov 25	9.41
Nov 25	9.12
Nov 25	9.92
Nov 25	10.2
Oct 25	11.15
Oct 25	10.99
Oct 25	10.99
Oct 25	10.67
Oct 25	12.87
Sep 25	12.34
Sep 25	11.92
Sep 25	11.44
Sep 25	11.48
Aug 25	10.38
Aug 25	10.5
Aug 25	9.8
Aug 25	9.17
Aug 25	9.64
Jul 25	9.76
Jul 25	8.91
Jul 25	8.2
Jul 25	7.8
Jun 25	7.7
Jun 25	7.26
Jun 25	8.4
Jun 25	7.4
May 25	7.64
May 25	7.38
May 25	7.26
May 25	7.1
May 25	7.53
Apr 25	7.09
Apr 25	6.27
Apr 25	6.25
Apr 25	7.03
Mar 25	10.36
Mar 25	10.5
Mar 25	10.66
Mar 25	9.47
Feb 25	8.9
Feb 25	10.34
Feb 25	9.01
Feb 25	8.38
Jan 25	7.28
Jan 25	7.17
Jan 25	7.13
Jan 25	6.56
Jan 25	6.59
Dec 24	6.7
Dec 24	6.65
Dec 24	6.89
Dec 24	6.66
Nov 24	5.61
Nov 24	5.46
Nov 24	5.66
Nov 24	6.31
Nov 24	6.11
Oct 24	6.58
Oct 24	6.24

Price/Operating Cashflow

WXXWY Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Sep 26	15.92
Sep 26	16.64
Aug 26	17.18
Aug 26	17.14
Aug 26	15.82
Aug 26	15.54
Jul 26	13.15
Jul 26	13.29
Jul 26	12.72
Jul 26	12.93
Jul 26	12.15
Jun 26	11.55
Jun 26	10.34
Jun 26	10.54
Jun 26	10.93
May 26	11.6
May 26	11.13
May 26	11.44
May 26	11.1
May 26	11.53
Apr 26	11.66
Apr 26	12.65
Apr 26	12.37
Apr 26	12.19
Mar 26	14.99
Mar 26	15.34
Mar 26	16.16
Mar 26	16.88
Feb 26	18.75
Feb 26	19.27
Feb 26	19.51
Feb 26	18.12
Jan 26	17.51
Jan 26	18.7
Jan 26	18.99
Jan 26	17.84
Jan 26	15.64
Dec 25	15.8
Dec 25	16.4
Dec 25	15.79
Dec 25	15.9
Nov 25	15.35
Nov 25	14.9
Nov 25	16.12
Nov 25	16.55
Oct 25	18.03
Oct 25	17.77
Oct 25	17.78
Oct 25	17.29
Oct 25	20.68
Sep 25	14.76
Sep 25	14.28
Sep 25	13.72
Sep 25	13.77
Aug 25	12.51
Aug 25	12.65
Aug 25	11.85
Aug 25	11.12
Aug 25	11.66
Jul 25	11.79
Jul 25	10.82
Jul 25	10
Jul 25	9.55
Jun 25	9.43
Jun 25	8.93
Jun 25	10.23
Jun 25	9.08
May 25	9.36
May 25	9.06
May 25	8.93
May 25	8.74
May 25	9.23
Apr 25	8.73
Apr 25	7.79
Apr 25	7.77
Apr 25	8.66
Mar 25	10.35
Mar 25	10.49
Mar 25	10.64
Mar 25	9.51
Feb 25	8.96
Feb 25	10.34
Feb 25	9.07
Feb 25	8.47
Jan 25	7.42
Jan 25	7.32
Jan 25	7.27
Jan 25	6.73
Jan 25	6.77
Dec 24	6.87
Dec 24	6.82
Dec 24	7.05
Dec 24	6.83
Nov 24	5.83
Nov 24	5.69
Nov 24	5.88
Nov 24	6.5
Nov 24	6.31
Oct 24	6.75
Oct 24	6.43

Price to Book

WXXWY Price to Book by quarter
Period	Price to Book
Sep 26	3.02
Sep 26	3.16
Aug 26	3.26
Aug 26	3.25
Aug 26	3
Aug 26	2.95
Jul 26	2.5
Jul 26	2.52
Jul 26	2.41
Jul 26	2.45
Jul 26	2.31
Jun 26	2.19
Jun 26	1.96
Jun 26	2
Jun 26	2.07
May 26	2.2
May 26	2.11
May 26	2.17
May 26	2.11
May 26	2.19
Apr 26	2.21
Apr 26	2.4
Apr 26	2.35
Apr 26	2.31
Mar 26	2.39
Mar 26	2.44
Mar 26	2.57
Mar 26	2.69
Feb 26	2.99
Feb 26	3.07
Feb 26	3.11
Feb 26	2.89
Jan 26	2.79
Jan 26	2.98
Jan 26	3.03
Jan 26	2.84
Jan 26	2.49
Dec 25	2.52
Dec 25	2.61
Dec 25	2.52
Dec 25	2.53
Nov 25	2.44
Nov 25	2.37
Nov 25	2.57
Nov 25	2.64
Oct 25	2.87
Oct 25	2.83
Oct 25	2.83
Oct 25	2.75
Oct 25	3.29
Sep 25	3.21
Sep 25	3.1
Sep 25	2.98
Sep 25	2.99
Aug 25	2.72
Aug 25	2.75
Aug 25	2.58
Aug 25	2.42
Aug 25	2.53
Jul 25	2.56
Jul 25	2.35
Jul 25	2.17
Jul 25	2.07
Jun 25	2.05
Jun 25	1.94
Jun 25	2.22
Jun 25	1.97
May 25	2.04
May 25	1.97
May 25	1.94
May 25	1.9
May 25	2.01
Apr 25	1.9
Apr 25	1.69
Apr 25	1.69
Apr 25	1.88
Mar 25	2.33
Mar 25	2.36
Mar 25	2.4
Mar 25	2.14
Feb 25	2.02
Feb 25	2.33
Feb 25	2.04
Feb 25	1.91
Jan 25	1.67
Jan 25	1.65
Jan 25	1.64
Jan 25	1.52
Jan 25	1.52
Dec 24	1.55
Dec 24	1.54
Dec 24	1.59
Dec 24	1.54
Nov 24	1.31
Nov 24	1.28
Nov 24	1.32
Nov 24	1.46
Nov 24	1.42
Oct 24	1.52
Oct 24	1.45

No video analysis for this stock yet. Request one from our team.

News: WXXWY

seekingalpha.com · 27 Aug 2026

WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2026 Earnings Call Transcript

defenseworld.net · 12 Aug 2026

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Down 81.8% in July

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 46,353 shares, a drop of 81.8% from the July 15th total of 255,103 shares. Based on an average daily volume of 113,253

prnewswire.com · 24 Jun 2026

WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations

SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached expected levels, demonstrating robust process performance and strong execution capabilities.

prnewswire.com · 18 Jun 2026

WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market

SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the fourth time the facility has successfully received EMA GMP certificate.